156 related articles for article (PubMed ID: 20855083)
1. Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice.
Nonaka K; Onizuka S; Ishibashi H; Uto Y; Hori H; Nakayama T; Matsuura N; Kanematsu T; Fujioka H
J Surg Res; 2012 Jan; 172(1):116-22. PubMed ID: 20855083
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf.
Kalkunte S; Brard L; Granai CO; Swamy N
Angiogenesis; 2005; 8(4):349-60. PubMed ID: 16400520
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.
Yamamoto N; Naraparaju VR
Cancer Res; 1997 Jun; 57(11):2187-92. PubMed ID: 9187119
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice.
Kisker O; Onizuka S; Becker CM; Fannon M; Flynn E; D'Amato R; Zetter B; Folkman J; Ray R; Swamy N; Pirie-Shepherd S
Neoplasia; 2003; 5(1):32-40. PubMed ID: 12659668
[TBL] [Abstract][Full Text] [Related]
5. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
6. Mitogen-activated protein kinase pathway mediates DBP-maf-induced apoptosis in RAW 264.7 macrophages.
Gumireddy K; Reddy CD; Swamy N
J Cell Biochem; 2003 Sep; 90(1):87-96. PubMed ID: 12938159
[TBL] [Abstract][Full Text] [Related]
7. Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells.
Pacini S; Punzi T; Morucci G; Gulisano M; Ruggiero M
Anticancer Res; 2012 Jan; 32(1):45-52. PubMed ID: 22213287
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
9. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
10. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling.
Man K; Ng KT; Xu A; Cheng Q; Lo CM; Xiao JW; Sun BS; Lim ZX; Cheung JS; Wu EX; Sun CK; Poon RT; Fan ST
Clin Cancer Res; 2010 Feb; 16(3):967-77. PubMed ID: 20103676
[TBL] [Abstract][Full Text] [Related]
11. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
12. The effects of vitamin D binding protein-macrophage activating factor and colony-stimulating factor-1 on hematopoietic cells in normal and osteopetrotic rats.
Benis KA; Schneider GB
Blood; 1996 Oct; 88(8):2898-905. PubMed ID: 8874186
[TBL] [Abstract][Full Text] [Related]
13. [Gene transfection of endostatin synergizes with doxorubicin to suppress human hepatocellular carcinomas: experiment with mice].
Liu FJ; Tan G; Li J; Sun XY
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2147-51. PubMed ID: 19080480
[TBL] [Abstract][Full Text] [Related]
14. Effects of vitamin D binding protein-macrophage activating factor (DBP-MAF) infusion on bone resorption in two osteopetrotic mutations.
Schneider GB; Benis KA; Flay NW; Ireland RA; Popoff SN
Bone; 1995 Jun; 16(6):657-62. PubMed ID: 7669443
[TBL] [Abstract][Full Text] [Related]
15. [Inhibition of growth and metastasis of hepatocellular carcinoma by rapamycin: experiment with mice].
Wang Z; Fan J; Zhou J; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1666-70. PubMed ID: 16854316
[TBL] [Abstract][Full Text] [Related]
16. A novel assay system for macrophage-activating factor activity using a human U937 cell line.
Ishikawa M; Inoue T; Inui T; Kuchiike D; Kubo K; Uto Y; Nishikata T
Anticancer Res; 2014 Aug; 34(8):4577-81. PubMed ID: 25075102
[TBL] [Abstract][Full Text] [Related]
17. [Up-regulation of thymidine phosphorylase and anti-angiogenesis by interferon alpha in human hepatocellular carcinoma cell line and xenograft].
Xiao YS; Zhou J; Tang ZY; Fan J; Wu ZQ; Liu YK; Ye SL; Shen ZZ; Xue Q; Zhao Y
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3205-9. PubMed ID: 16405841
[TBL] [Abstract][Full Text] [Related]
18. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
19. The toothless osteopetrotic rat has a normal vitamin D-binding protein-macrophage activating factor (DBP-MAF) cascade and chondrodysplasia resistant to treatments with colony stimulating factor-1 (CSF-1) and/or DBP-MAF.
Odgren PR; Popoff SN; Safadi FF; MacKay CA; Mason-Savas A; Seifert MF; Marks SC
Bone; 1999 Aug; 25(2):175-81. PubMed ID: 10456382
[TBL] [Abstract][Full Text] [Related]
20. Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma.
Zhao X; Li J; Zhuo J; Cai L
Biochem Biophys Res Commun; 2010 Dec; 403(3-4):417-21. PubMed ID: 21093415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
